Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody. Here, we evaluate the functional and anatomical outcomes of faricimab treatment in patients with diabetic macular edema (DME) that was r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohara, Hiromi, Harada, Yosuke, Hiyama, Tomona, Sadahide, Ayako, Minamoto, Akira, Kiuchi, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302733/
https://www.ncbi.nlm.nih.gov/pubmed/37374329
http://dx.doi.org/10.3390/medicina59061125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302733/
https://www.ncbi.nlm.nih.gov/pubmed/37374329
http://dx.doi.org/10.3390/medicina59061125

Ejemplares similares